Bristol Myers Squibb Stock Probability Of Bankruptcy

BMY Stock

USD 58.87 0.64 1.10%

Bristol Myers' odds of distress is under 14% at this time. It has tiny probability of undergoing some form of financial hardship in the near future. Probability of bankruptcy shows the probability of financial torment over the next two years of operations under current economic and market conditions. All items used in analyzing the odds of distress are taken from the Bristol balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out Bristol Myers Piotroski F Score and Bristol Myers Altman Z Score analysis.

Market Cap is likely to rise to about 108.4 B in 2024. Enterprise Value is likely to rise to about 112.4 B in 2024

Bristol Myers Squibb Company probability of bankruptcy Analysis

Bristol Myers' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current Bristol Myers Probability Of Bankruptcy

Less than 14%

Most of Bristol Myers' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bristol Myers Squibb is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Our calculation of Bristol Myers probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Bristol Myers odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Bristol Myers Squibb financial health.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.36)

Dividend Share

2.4

Earnings Share

(3.58)

Revenue Per Share

23.41

Quarterly Revenue Growth

0.084

The market value of Bristol Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Bristol Probability Of Bankruptcy Driver Correlations

Understanding the fundamental principles of building solid financial models for Bristol Myers is extremely important. It helps to project a fair market value of Bristol Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Bristol Myers' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bristol Myers' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bristol Myers' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Good Will	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Short Term Investments	Capital Stock	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Total Permanent Equity	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital
Total Assets		0.89	0.98	-0.07	0.76	0.97	0.99	0.94	0.85	0.96	0.6	0.12	0.88	0.88	0.98	-0.76	0.83	0.61	-0.97	0.37	0.97	0.93	0.79	-0.5	-0.35	0.91	0.98	0.86
Total Stockholder Equity	0.89		0.84	0.13	0.5	0.82	0.85	0.76	0.73	0.93	0.62	0.36	0.81	0.81	0.85	-0.51	0.73	0.33	-0.87	0.28	0.81	0.73	0.82	-0.51	-0.31	0.83	0.89	0.79
Net Debt	0.98	0.84		-0.17	0.82	0.98	0.99	0.93	0.89	0.94	0.56	-0.02	0.91	0.91	0.99	-0.82	0.87	0.66	-0.99	0.44	0.99	0.97	0.76	-0.54	-0.37	0.93	0.98	0.85
Retained Earnings	-0.07	0.13	-0.17		-0.11	-0.03	-0.11	-0.05	-0.16	-0.13	0.44	0.49	-0.15	-0.15	-0.17	0.05	-0.07	-0.44	0.19	-0.45	-0.23	-0.26	-0.07	0.43	-0.13	-0.21	-0.19	-0.16
Net Receivables	0.76	0.5	0.82	-0.11		0.88	0.8	0.86	0.87	0.62	0.53	-0.15	0.81	0.81	0.8	-0.98	0.84	0.69	-0.75	0.54	0.82	0.9	0.33	-0.35	-0.51	0.73	0.75	0.63
Good Will	0.97	0.82	0.98	-0.03	0.88		0.98	0.95	0.9	0.9	0.63	0.03	0.9	0.9	0.97	-0.88	0.88	0.65	-0.95	0.41	0.97	0.97	0.7	-0.47	-0.42	0.9	0.95	0.82
Total Liab	0.99	0.85	0.99	-0.11	0.8	0.98		0.96	0.87	0.94	0.61	0.05	0.9	0.9	0.99	-0.81	0.85	0.64	-0.98	0.4	0.98	0.95	0.77	-0.51	-0.37	0.93	0.97	0.86
Total Current Assets	0.94	0.76	0.93	-0.05	0.86	0.95	0.96		0.85	0.84	0.68	0.07	0.86	0.86	0.94	-0.86	0.81	0.67	-0.89	0.37	0.94	0.94	0.61	-0.4	-0.36	0.87	0.9	0.82
Short Term Debt	0.85	0.73	0.89	-0.16	0.87	0.9	0.87	0.85		0.82	0.53	0.05	0.84	0.84	0.87	-0.83	0.85	0.56	-0.87	0.57	0.87	0.9	0.6	-0.48	-0.43	0.87	0.88	0.75
Intangible Assets	0.96	0.93	0.94	-0.13	0.62	0.9	0.94	0.84	0.82		0.5	0.17	0.83	0.83	0.95	-0.62	0.78	0.52	-0.97	0.39	0.93	0.87	0.88	-0.63	-0.32	0.93	0.98	0.87
Accounts Payable	0.6	0.62	0.56	0.44	0.53	0.63	0.61	0.68	0.53	0.5		0.19	0.64	0.64	0.56	-0.61	0.6	0.09	-0.54	-0.13	0.52	0.51	0.39	-0.01	-0.13	0.5	0.51	0.4
Short Term Investments	0.12	0.36	-0.02	0.49	-0.15	0.03	0.05	0.07	0.05	0.17	0.19		-0.04	-0.04	0.04	0.21	-0.1	-0.23	-0.02	-0.17	-0.02	-0.09	0.24	0.09	-0.05	0.16	0.1	0.3
Capital Stock	0.88	0.81	0.91	-0.15	0.81	0.9	0.9	0.86	0.84	0.83	0.64	-0.04		1.0	0.9	-0.83	0.95	0.67	-0.9	0.46	0.91	0.92	0.64	-0.52	-0.35	0.86	0.9	0.78
Common Stock	0.88	0.81	0.91	-0.15	0.81	0.9	0.9	0.86	0.84	0.83	0.64	-0.04	1.0		0.9	-0.83	0.95	0.67	-0.9	0.46	0.91	0.92	0.64	-0.52	-0.35	0.86	0.9	0.78
Long Term Debt	0.98	0.85	0.99	-0.17	0.8	0.97	0.99	0.94	0.87	0.95	0.56	0.04	0.9	0.9		-0.8	0.85	0.66	-0.99	0.45	1.0	0.96	0.76	-0.58	-0.4	0.96	0.99	0.89
Treasury Stock	-0.76	-0.51	-0.82	0.05	-0.98	-0.88	-0.81	-0.86	-0.83	-0.62	-0.61	0.21	-0.83	-0.83	-0.8		-0.87	-0.7	0.76	-0.41	-0.81	-0.9	-0.37	0.31	0.4	-0.7	-0.74	-0.59
Property Plant Equipment	0.83	0.73	0.87	-0.07	0.84	0.88	0.85	0.81	0.85	0.78	0.6	-0.1	0.95	0.95	0.85	-0.87		0.67	-0.86	0.54	0.86	0.89	0.64	-0.55	-0.47	0.8	0.84	0.72
Current Deferred Revenue	0.61	0.33	0.66	-0.44	0.69	0.65	0.64	0.67	0.56	0.52	0.09	-0.23	0.67	0.67	0.66	-0.7	0.67		-0.62	0.5	0.73	0.78	0.39	-0.45	-0.2	0.6	0.65	0.68
Net Tangible Assets	-0.97	-0.87	-0.99	0.19	-0.75	-0.95	-0.98	-0.89	-0.87	-0.97	-0.54	-0.02	-0.9	-0.9	-0.99	0.76	-0.86	-0.62		-0.44	-0.98	-0.94	-0.83	0.6	0.35	-0.95	-0.99	-0.86
Total Permanent Equity	0.37	0.28	0.44	-0.45	0.54	0.41	0.4	0.37	0.57	0.39	-0.13	-0.17	0.46	0.46	0.45	-0.41	0.54	0.5	-0.44		0.49	0.52	0.17	-0.75	-0.76	0.51	0.48	0.45
Long Term Debt Total	0.97	0.81	0.99	-0.23	0.82	0.97	0.98	0.94	0.87	0.93	0.52	-0.02	0.91	0.91	1.0	-0.81	0.86	0.73	-0.98	0.49		0.98	0.74	-0.6	-0.39	0.95	0.98	0.89
Capital Surpluse	0.93	0.73	0.97	-0.26	0.9	0.97	0.95	0.94	0.9	0.87	0.51	-0.09	0.92	0.92	0.96	-0.9	0.89	0.78	-0.94	0.52	0.98		0.65	-0.56	-0.37	0.9	0.95	0.82
Deferred Long Term Liab	0.79	0.82	0.76	-0.07	0.33	0.7	0.77	0.61	0.6	0.88	0.39	0.24	0.64	0.64	0.76	-0.37	0.64	0.39	-0.83	0.17	0.74	0.65		-0.51	-0.11	0.76	0.8	0.78
Long Term Investments	-0.5	-0.51	-0.54	0.43	-0.35	-0.47	-0.51	-0.4	-0.48	-0.63	-0.01	0.09	-0.52	-0.52	-0.58	0.31	-0.55	-0.45	0.6	-0.75	-0.6	-0.56	-0.51		0.55	-0.65	-0.63	-0.6
Short Long Term Debt	-0.35	-0.31	-0.37	-0.13	-0.51	-0.42	-0.37	-0.36	-0.43	-0.32	-0.13	-0.05	-0.35	-0.35	-0.4	0.4	-0.47	-0.2	0.35	-0.76	-0.39	-0.37	-0.11	0.55		-0.46	-0.38	-0.39
Cash And Equivalents	0.91	0.83	0.93	-0.21	0.73	0.9	0.93	0.87	0.87	0.93	0.5	0.16	0.86	0.86	0.96	-0.7	0.8	0.6	-0.95	0.51	0.95	0.9	0.76	-0.65	-0.46		0.96	0.94
Net Invested Capital	0.98	0.89	0.98	-0.19	0.75	0.95	0.97	0.9	0.88	0.98	0.51	0.1	0.9	0.9	0.99	-0.74	0.84	0.65	-0.99	0.48	0.98	0.95	0.8	-0.63	-0.38	0.96		0.89
Net Working Capital	0.86	0.79	0.85	-0.16	0.63	0.82	0.86	0.82	0.75	0.87	0.4	0.3	0.78	0.78	0.89	-0.59	0.72	0.68	-0.86	0.45	0.89	0.82	0.78	-0.6	-0.39	0.94	0.89

Click cells to compare fundamentals

The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.

Competition

Predict Bristol Myers

Based on the latest financial disclosure, Bristol Myers Squibb has a Probability Of Bankruptcy of 14.0%. This is 67.66% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 64.85% higher than that of the company.

Bristol Probability Of Bankruptcy Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bristol Myers' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bristol Myers could also be used in its relative valuation, which is a method of valuing Bristol Myers by comparing valuation metrics of similar companies.

Bristol Myers is currently under evaluation in probability of bankruptcy category among its peers.

Bristol Myers Main Bankruptcy Drivers

	2019	2020	2021	2022	2023	2024 (projected)
Return On Assets	0.46	0.0265	(0.0759)	0.064	0.0653	0.0843
Asset Turnover	0.62	2.12	0.2	0.36	0.48	0.88
Net Debt	35.2B	37.1B	31.6B	31.6B	30B	31.5B
Total Current Liabilities	18.3B	19.1B	21.9B	21.9B	22.3B	23.4B
Non Current Liabilities Total	59.9B	61.5B	51.4B	43.8B	43.4B	45.6B
Total Assets	129.9B	118.5B	109.3B	96.8B	95.2B	99.9B
Total Current Assets	29.4B	30.2B	33.3B	27.3B	31.8B	33.4B
Total Cash From Operating Activities	8.1B	14.1B	16.2B	13.1B	13.9B	14.6B

Bristol Myers ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bristol Myers' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bristol Myers' managers, analysts, and investors.

Environmental

Governance

Social

Bristol Fundamentals

	Return On Equity	-0.31
	Return On Asset	0.0607
	Profit Margin	(0.15) %
	Operating Margin	0.18 %
	Current Valuation	162.7 B
	Shares Outstanding	2.03 B
	Shares Owned By Insiders	0.11 %
	Shares Owned By Institutions	78.41 %
	Number Of Shares Shorted	23.42 M
	Price To Earning	24.88 X
	Price To Book	6.97 X
	Price To Sales	2.52 X
	Revenue	45.01 B
	Gross Profit	36.38 B
	EBITDA	19.42 B
	Net Income	8.04 B
	Cash And Equivalents	9.12 B
	Cash Per Share	6.21 X
	Total Debt	41.46 B
	Debt To Equity	1.32 %
	Current Ratio	1.42 X
	Book Value Per Share	8.45 X
	Cash Flow From Operations	13.86 B
	Short Ratio	2.30 X
	Earnings Per Share	(3.58) X
	Price To Earnings To Growth	2.06 X
	Target Price	59.37
	Number Of Employees	34.1 K
	Beta	0.44
	Market Capitalization	119.4 B
	Total Asset	95.16 B
	Retained Earnings	28.77 B
	Working Capital	9.51 B
	Current Asset	10.41 B
	Current Liabilities	8.02 B
	Annual Yield	0.04 %
	Five Year Return	2.96 %
	Net Asset	95.16 B
	Last Dividend Paid	2.4

About Bristol Myers Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bristol Myers Squibb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bristol Myers using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bristol Myers Squibb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Bristol Stock Analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bristol Myers Squibb Stock Probability Of Bankruptcy

Bristol Myers Squibb Company probability of bankruptcy Analysis

Probability Of Bankruptcy

Normalized

Z-Score

Current Bristol Myers Probability Of Bankruptcy

Bristol Probability Of Bankruptcy Driver Correlations

Bristol Probability Of Bankruptcy Peer Comparison

Bristol Myers Main Bankruptcy Drivers

Bristol Myers ESG Sustainability

Bristol Fundamentals

About Bristol Myers Fundamental Analysis

Also Currently Popular

Additional Tools for Bristol Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY